利培酮治疗复发性精神分裂症的临床对照研究  

A controlled trial comparing the efficacy of risperidone in the treatment of the recurrent schizophrenia

作　　者：郭芝芳[1] 师建国[1] 戴尊孝[1] 杨洪[1] 

机构地区：[1]西安市精神卫生中心,陕西西安710061

出　　处：《中国行为医学科学》2001年第6期575-577,共3页Chinese Journal of Behavioral Medical Science

摘　　要：目的　验证利培酮治疗复发性精神分裂症的疗效和安全性。方法　对 53例复发性精神分裂症患者用利培酮治疗 ,并于 51例首发精神分裂症进行对照 ,疗程为 1 6周。采用简明精神病评定量表 (BPRS)评定疗效 ,副反应量表 (TESS)评定不良反应。结果　利培酮治疗复发性精神分裂症的疗效、依从性、副作用与首发精神分裂症相似。结论　利培酮也是治疗复发性精神分裂症的安全、有效的新型抗精神病药物。Objective To observe the efficacy and safety of risperidone in the treatment of recurrent schizophrenia.Methods A total of 53 recurrent patients and 51 first onset patients who met CCMD 2 R and ICD 10 criteria for schizophrenia were treated of risperidone to included in this 16 weeks clinical study. The efficacy was measured with Brief Psychiatric Rating Scale (BPRS) and the adverse events was determined with Treatment Emergent Symptoms Scale (TESS).Results There was no significant difference between two groups in overall response rate showed by the reduction rate of BPRS total scores and overall incidence of the adverse events. Conclusions Risperidone appears to be as effective as in treatment of recurrent schizophrenia than first onset patients.

关 键 词：利培酮 复发性精神分裂症 首发精神分裂症 抗精神病药物 

分 类 号：R749.3[医药卫生—神经病学与精神病学] R971.4[医药卫生—临床医学]